Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

Morel, Pierre;Munck, Jean-Nicolas;Coiffier, Bertrand;Gisselbrecht, Christian;Reyes, Felix;et.al.
(2010) Leukemia and Lymphoma — Vol. 51, n° 9, p. 1668-1677 (2010)

Files

MorelPetalLeukemiaandLymphoma2010.pdf
  • Restricted Access
  • Adobe PDF
  • 456.02 KB
Request a copy

Details

Authors
  • Morel, Pierre
    Author
  • Munck, Jean-Nicolas
    Author
  • Coiffier, Bertrand
    Author
  • Gisselbrecht, Christian
    Author
  • Bosly, AndréUCLouvain
    Author
  • Reyes, Felix
    Author
Show more
Abstract
One-third of patients aged <= 60 years with aggressive lymphoma are at low-intermediate risk (LIR). Before the rituximab era, we prospectively compared ACVBP with ECVBP, a similar regimen including epirubicin instead of doxorubicin and increased dose intensity of cyclophosphamide, followed by conventional consolidation with an increased amount and dose intensity of cytosine-arabinoside, methotrexate, etoposide, and ifosfamide, in 652 patients with LIR aggressive lymphoma. The overall response rate, 5-year event-free survival (EFS), and survival were estimated to be 86%, 60%, and 74%, respectively, with no differences between the two arms. In patients with diffuse large B-cell lymphoma (DLBCL) who received ACVBP, the 5-year EFS and survival were estimated at 69% and 82%. These findings do not support the use of a chemotherapy regimen more intensive than ACVBP in patients aged <= 60 years with LIR aggressive lymphoma. The results in the control arm, without rituximab, have led to a randomized comparison of R-ACVBP and R-CHOP in this patient population.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Morel, P., Munck, J.-N., Coiffier, B., Gisselbrecht, C., Ranta, D., Bosly, A., Tilly, H., Quesnel, B., Thyss, A., Mounier, N., Briere, J., Molina, T., & Reyes, F. (2010). Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. Leukemia and Lymphoma, 51(9), 1668-1677. https://doi.org/10.3109/10428194.2010.504871 (Original work published 2010)